Литература/References

Поставить закладку

Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–8.
Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the management of ar- terial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013.
Funder JW, Carey RM, Mantero F et al. The Management of Primary Aldosteronism Case Detection Diagnosis and Treatment An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–916.
Funder JW, Carey RM, Fardella C et al. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metab 2008; 93 (9): 3266–81.
Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J lab Clin Med 1955; 45: 3–17.
Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic Primary Aldosteronism. A Detectable Cause of Curable “Essential” Hypertension. Jama 1965; 193: 200–6.
Conn JW. The Evolution of Primary Aldosteronism 1954–1967. Acedemic Press Inc.
Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med 1967; 66: 1079–90.
Fishman LM, Kuchel O, Liddle GW et al. Incidence of primary aldosteronism uncomplica- ted “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. Jama 1968; 205: 497–502.
Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hyperten- sion: studies in a random population sample. Br Med J 1976; 2: 554–6.
Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 1977; 52: 549–5.
Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67: 403–13.
Sinclair AM, Isles CG, Brown I et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289–93.
Andersen GS, Toftdahl DB, Lund JO et al. The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977–1981. J Hum Hypertens 1988; 2: 187–9.
Grim CE, Weinberger MH, Higgins JT, Kramer NJ. Diagnosis of secondary forms of hyper- tension. A comprehensive protocol. JAMA 1977; 237: 1331–5.
Gordon RD, Stowasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–8.
Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863–7.
Lim PO, Dow E, Brennan G et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311–5.
Loh KC, Koay ES, Khaw MC et al. Prevalence of primary aldosteronism among Asian hy- pertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854–9.
Mulatero P, Stowasser M, Loh KC et al. Increased diagnosis of primary aldosteronism, in- cluding surgically correctable forms, in centers from five continents. J Clinic Endocrinol Metabo 2004; 89: 1045–50.
Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin acti- vity. Clin Chem 2005; 51: 386–94.
Hannemann A, Bidlingmaier M, Friedrich N et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7–15.
Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary al- dosteronism in 1.125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–300.
Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–8.
Stowasser M, Sharman J, Leano R et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin En- docrinol and Metab 2005; 90: 5070–6.
Rossi GP, Cesari M, Cuspidi C et al. Long-term control of arterial hypertension and regres- sion of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62–9.
Reincke M, Fischer E, Gerum S et al. German Conn’s Registry-Else Kroner-Fresenius-Hy- peraldosteronism R. Observational study mortality in treated primary aldosteronism. The German Conn's Registry. Hypertension 2012; 60 (3): 618–24.
Lin YH, Lin LY, Chen A et al. Adrenalectomy improves increased carotid intima-media thic- kness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclero- sis 2012; 221: 154–9.
Stowasser M, Gordon RD, Gunasekera TG et al. High rate of detection of primary aldoste- ronism, including surgically treatable forms, after ‘nonselective’ screening of hypertensive patients. J Hypertens 2003; 21: 2149–57.
Catena C, Colussi G, Lapenna R et al. Long-term cardiac effects of adrenalectomy or mi- neralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911–8.
Wu VC, Kuo CC, Wang SM et al. Primary aldosteronism: changes in cystatin C-based kid- ney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 2011; 29: 1778–86.
трошина еа, Бельцевич дГ, молашенко нв. диагностика и дифференциальная диагностика первичного гиперальдостеронизма. клин. медицина. 2009; 5: 15–20. / Troshina EA, Bel'tsevich DG, Molashenko NV. Diagnostika i differentsial'naia diagnostika pervichnogo giperal'dosteronizma. Klin. meditsina. 2009; 5: 15–20. [in Russian]
Montori VM, Schwartz GL, Chapman AB et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877–882.
Stowasser M, Ahmed AH, Pimenta E et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170–6.
Montori VM, Schwartz GL, Chapman AB et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877–82.
Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863–7.
Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161–5.
Gallay BJ, Ahmad S, Xu L et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699–705.
Tiu SC, Choi CH, Shek CC et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72–8.
Solar M, Malirova E, Ballon M et al. Confirmatory testing in primary aldosteronism: exten- sive medication switching is not needed in all patients. Eur J Endocrinol 2012; 166: 679–86.
Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607–18.
Young WF. Conventional imaging in adrenocortical carcinoma: update and perspectives. Horm canc 2011; 2: 341–7.
Nwariaku FE, Miller BS, Auchus R et al. Primary hyperaldosteronism: effect of adrenal ve- in sampling on surgical outcome. Arch Surg 2006; 141: 497–502.
Sawka AM, Young WF, Thompson GB et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258–61.
Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary al- dosteronism. World J Surg 2005; 29: 155–9.
Weinberger MH, Grim CE, Hollifield JW et al. Primary aldosteronism: diagnosis, localiza- tion, and treatment. Ann Intern Med 1979; 90: 386–95.
Baer L, Sommers SC, Krakoff LR et al. Pseudoprimary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 1970; 27: 203–20.
Priestley JT, Ferris DO, ReMine WH, Woolner LB. Primary aldosteronism: surgical mana- gement and pathologic findings. Mayo Clin Proc 1968; 43: 761–75.
Young WF, Stanson AW, Thompson GB et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227–35.
Doppman JL, Gill JR. Hyperaldosteronism: sampling the adrenal veins. Radiology 1996; 198: 309–12.
Vonend O, Ockenfels N, Gao X et al. Adrenal venous sampling: evaluation of the German Conn’s registry. Hypertension 2011; 57: 990–5.
Mengozzi G, Rossato D, Bertello C et al. Rapid cortisol assay during adrenal vein sam- pling in patients with primary aldosteronism. Clin Chem 2007; 53: 1968–71.
Auchus RJ, Michaelis C, Wians FH et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009; 249: 318–21.
Reardon MA, Angle JF, Abi-Jaoudeh N et al. Intraprocedural cortisol levels in the evalua- tion of proper catheter placement in adrenal venous sampling. J Vascular Interv Radiol 2011; 22: 1575–80.
Rossi GP. Diagnosis and treatment of primary aldosteronism. Endocrinol Metab Clin North Am 2011; 40: 313–32.
Betz MJ, Degenhart C, Fischer E et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011; 165: 301–6.
Viste K, Grytaas MA, Jorstad MD et al. Efficacy of adrenal venous sampling is increased by point of care cortisol analysis. Endocr Connect 2013; 2: 236–42.
Riester A, Fischer E, Degenhart C et al. Age below 40 or a recently proposed clinical pre- diction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin En- docrinol Metab 2014; 99: E1035–9.
Lim V, Guo Q, Grant CS et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99: 2712–19.
Rossi GP, Barisa M, Allolio B et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012; 97: 1606–14.
Stowaser M et al. Diagnosis and management of primary aldosteronism. J Renin Angio- tensin Aldosterone Syst 2001; 2; 156–69.
Rossi GP, Auchus RJ, Brown M et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63: 151–60.
Webb R, Mathur A, Chang R et al. What is the best criterion for the interpretation of adre- nal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol 2012; 19: 1881–6.
McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev 2004; 12: 44–8.
Mulatero P, Tizzani D, Viola A et al. Prevalence and characteristics of familial hyperaldo- steronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hyper- tension 2011; 58: 797–803.
Dluhy RG, Anderson B, Harlin B et al. Glucocorticoid-remediable aldosteronism is asso- ciated with severe hypertension in early childhood. J Pediatr 2001; 138: 715–20.
Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta-hydroxylase/aldosterone synt- hase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Na- ture 1992; 355: 262–5.
Jonsson JR, Klemm SA, Tunny TJ et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565–71.
Fardella CE, Pinto M, Mosso L et al. Genetic study of patients with dexamethasone-sup- pressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001; 86: 4805–7.
So A, Duffy DL, Gordon RD et al. Familial hyperaldosteronism type II is linked to the chromo- some 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23: 1477–84.
Gordon RD, Stowasser M, Tunny TJ et al. Clinical and pathological diversity of primary al- dosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18 (5): 283–6.
Geller DS, Zhang J, Wisgerhof MV et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117–23.
Choi M, Scholl UI, Yue P et al. K channel mutations in adrenal aldosterone-producing ade- nomas and hereditary hypertension. Science 2011; 331: 768–72.
Scholl UI, Nelson-Williams C, Yue P et al. Hypertension with or without adrenal hyperpla- sia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA 2012; 109: 2533–8.
Blumenfeld JD, Sealey JE, Schlussel Y et al. Diagnosis and treatment of primary hyperal- dosteronism. Ann Intern Med 1994; 121: 877–85.
Harris DA, Au-Yong I, Basnyat PS et al. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol 2003; 29: 467–74.
Rossi E, Regolisti G, Negro A et al. High prevalence of primary aldosteronism using po- stcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensi- ves. Am J Hypertens 2002; 15: 896–902.
Young WF. Jr. Minireview: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208–13.
Lo CY, Tam PC, Kung AW et al. Primary aldosteronism. Results of surgical treatment. Ann Surg 1996; 224: 125–30.
Proye CA, Mulliez EA, Carnaille BM et al. Essential hypertension: first reason for persistent hy- pertension after unilateral adrenalectomy for primary aldosteronism? Surg 1998; 124: 1128–33.
Wu VC, Kuo CC, Wang SM et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 2011; 29: 1778–86.
Fourkiotis V, Vonend O, Diederich S et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2013; 168: 75–81.
Sawka AM, Young WF, Thompson GB et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258–61.
Ishidoya S, Ito A, Sakai K et al. Laparoscopic partial versus total adrenalectomy for aldo- sterone producing adenoma. J Urol 2005; 174 (1): 40–3.
Ghose RP, Hall PM, Bravo EL. The classic presenting signs of primary aldosteronism are hypertension. Br J Clin Pharmacol 1999; 48: 756.
Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2 (4): 198–208.
Fischer E, Hanslik G, Pallauf A et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965–73.
Weinberger MH, Grim CE, Hollifield JW et al. Primary aldosteronism: diagnosis, localiza- tion, and treatment. Ann Intern Med 1979; 90: 386–95.
Baer L, Sommers SC, Krakoff LR et al. Pseudo-primary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 1970; 27: 203–20.
Priestley JT, Ferris DO, ReMine WH, Woolner LB. Primary aldosteronism: surgical mana- gement and pathologic findings. Mayo Clin Proc 1968; 43: 761–75.
Parthasarathy HK, Menard J, White WB et al. A double-blind, randomized study compa- ring the antihypertensive effect of eplerenone and spironolactone in patients with hyper- tension and evidence of primary aldosteronism. J Hypertens 2011; 29 (5): 980–90.
Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9 (4): 509–15.
Donald TM. A double-blind, randomized study comparing the antihypertensive effect of ep- lerenone and spironolactone in patients with hypertension and evidence of primary aldo- steronism. J Hypertens 2011; 29: 980–90.
Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983–92.
Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients ith primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–48.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница